The following video is from this week's MarketFoolery podcast, in which host Chris Hill, along with Charly Travers and Joe Magyer, discuss the latest business news. In this segment, the guys analyze some companies in genome-related industries, including Illumina, Affymetrix, and Life Technologies. While some investors believe genome sequencing will be profitable for shareholders, Charly discusses why he believes the real winners will be consumers as sequencing becomes more of a commodity. For investors looking to profit from related industries, he shares three stocks he believes are worth a second look.
From biotech to consumer tech, there are companies that go public while still facing the challenge of generating growing revenue off their customer base. We've created a new report, "Forget Facebook -- Here's the Tech IPO You Should Be Buying," which details a much better consumer tech stock that has a longer runway for growth than Facebook. The report won't be available forever, so click here to get access today -- it's totally free,
At the time this article was published Chris Hill owns no shares of any of the companies mentioned. The Motley Fool owns shares of Bio-Reference Laboratories and Ancestry.com. Motley Fool newsletter services have recommended buying shares of Illumina and Ancestry.com. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.